pharmaphorum2d
First biosimilar fast-acting insulin reaches US market
Sanofi-Aventis' Merilog version of the ... Before Merilog, the FDA has given the go-ahead to two biosimilars of Sanofi's basal insulin product Lantus (insulin glargine) – Viatris' Semglee ...
WAGM-TV on MSN3d
Attorney General Aaron M. Frey Announces Settlement Agreement Will Bring $35 Insulin to Mainers
Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...
Maine announces settlement to reduce insulin costs
Under the settlement, Mainers who are uninsured or have commercial health insurance will be eligible to purchase monthly ...
WebMD23d
FDA OKs First Fast-Acting Insulin Biosimilar for Diabetes
With more people needing daily insulin, biosimilar options can make this lifesaving treatment more accessible. Merilog, made by Sanofi-Aventis, is a rapid-acting insulin biosimilar (similar to ...
JD Supra23d
FDA Approves First Rapid-Acting Insulin Biosimilar Product for the Treatment of Diabetes
the U.S. Food and Drug Administration (“FDA”) approved Sanofi-Aventis U.S. LLC’s (“Sanofi”) MERILOG™ (insulin-aspart-szjj), a biosimilar to Novo Nordisk A/S’s (“Novo Nordisk ...
FiercePharma25d
FDA signs off on Sanofi's insulin biosimilar, the first for Novo Nordisk's rapid-acting NovoLog
More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency ...
South African watchdog probes Novo Nordisk and Sanofi over insulin
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...
Business Insider29d
FDA approves Sanofi biosimilar product for treatment of diabetes
“Merilog, a rapid-acting human insulin analog ... The FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first on TheFly – the ultimate source for real-time, market ...
Hosted on MSN28d
Sanofi gets FDA approval for NovoLog insulin biosimilar
Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...
Nasdaq26d
FDA Approves Merilog Rapid-Acting Insulin Biosimilar For Diabetes
(RTTNews) - The U.S. Food and Drug Administration announced that Sanofi-Aventis U.S. LLC's Merilog (insulin-aspart-szjj) becomes the first rapid-acting insulin biosimilar product to get its ...
Pharmabiz26d
US FDA approves Sanofi-Aventis’ rapid-acting insulin biosimilar product Merilog for improvement of glycaemic control in patients with diabetes
The FDA granted approval of Merilog to Sanofi-Aventis U.S. LLC. “The FDA has now approved three biosimilar insulin products to treat diabetes,” said Peter Stein, M.D., director of the Office of New ...
Novo Nordisk, Sanofi Face South Africa Insulin Antitrust Probe
Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.